Loading stock data…
CLPT
$10.79-0.39 (-3.49%)
Market OpenUpdated 10:14 AM EDT
ClearPoint Neuro, Inc., a commercial-stage medical device company, focuses on the development and commercialization of platforms for performing minimally invasive surgical procedures in the brain in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
ClearPoint Neuro, Inc. in the Healthcare sector is trading at $11.18. The stock is currently near its 52-week low of $8.27, remaining 20.4% below its 200-day moving average. Technical signals show neutral RSI of 56 and bullish MACD crossover, explaining why CLPT maintains its current current market pressure. The Whystock Score of 35/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Neutral momentum (RSI 56) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$10.79
Potential Upside
5%
Whystock Fair Value$11.33
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus2 analysts
Mean target$25.00+131.7%
Range$20.00 – $30.00
Fundamentals
ClearPoint Neuro, Inc., a commercial-stage medical device company, focuses on the development and commercialization of platforms for performing minimally invasive surgical procedures in the brain in the United States. The company offers ClearPoint sy...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$314.55M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.18
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-91.15%
Volume
Today's trading volume
41,688
Recent News
UFP Technologies (UFPT) Tops Q1 Earnings Estimates
UFP (UFPT) delivered earnings and revenue surprises of +13.76% and -2.09%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Why The ClearPoint Neuro (CLPT) Investment Story Is Shifting On Regulatory And Partnership Risks
ClearPoint Neuro’s latest analyst update keeps the fair value estimate steady at US$25.00 per share, signaling no change to the formal price target in the current model. That stability sits alongside research commentary that blends optimism about the core business with caution around partner driven regulatory outcomes, which is feeding into how analysts think about risk rather than headline valuation alone. As you read on, you will see how this evolving narrative might shape expectations and...
Why The ClearPoint Neuro (CLPT) Story Is Shifting After New Partner And FDA Updates
ClearPoint Neuro’s updated fair value estimate sits at US$25.00, compared with the prior US$24.00, putting a fresh spotlight on how analysts are recalibrating expectations. This shift reflects a mix of renewed optimism around the company’s broad biopharma partner base and expedited intracranial programs, set against caution after regulatory feedback on a key partner trial. As you read on, you will see how these moving parts shape the evolving story and what to watch to stay ahead of the...
ClearPoint Neuro Q4 Earnings Call Highlights
ClearPoint Neuro (NASDAQ:CLPT) reported higher revenue for both the fourth quarter and full year 2025 and outlined a two-phase growth strategy that management said is designed to expand the company’s presence across multiple neurosurgical markets while positioning for longer-term opportunities in ce
ClearPoint Neuro, Inc. Q4 2025 Earnings Call Summary
Moby summary of ClearPoint Neuro, Inc.'s Q4 2025 earnings call